| Literature DB >> 34210036 |
Leticia Matilla-Cuenca1, Alejandro Toledo-Arana1, Jaione Valle1.
Abstract
The choice of an effective therapeutic strategy in the treatment of biofilm-related infections is a significant issue. Amyloids, which have been historically related to human diseases, are now considered to be prevailing structural components of the biofilm matrix in a wide range of bacteria. This assumption creates the potential for an exciting research area, in which functional amyloids are considered to be attractive targets for drug development to dissemble biofilm structures. The present review describes the best-characterized bacterial functional amyloids and focuses on anti-biofilm agents that target intrinsic and facultative amyloids. This study provides a better understanding of the different modes of actions of the anti-amyloid molecules to inhibit biofilm formation. This information can be further exploited to improve the therapeutic strategies to combat biofilm-related infections.Entities:
Keywords: amyloids; antibiotic resistance; biofilm; peptides; polyphenols
Year: 2021 PMID: 34210036 PMCID: PMC8300730 DOI: 10.3390/antibiotics10070795
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Classification of functional amyloids.
| Amyloid Type | Locus | Amyloid Subunits | Bacteria | |
|---|---|---|---|---|
| Intrinsic amyloids | ||||
| Curli |
| CsgA, CsgB |
| [ |
| Fap |
| FapC, FapB, |
| [ |
| MTP |
| MTP |
| [ |
| Chaplins/Rodlins |
| ChpD-H, RdlB |
| [ |
| Facultative amyloids | ||||
| PSMs |
| PSMα, PSMβ, δ-toxin |
| [ |
| TasA |
| TasA |
| [ |
| Bap |
| BapB-domain |
| [ |
| Esp |
| N-terminal domain |
| [ |
| P1 |
| AgII-C123 region |
| [ |
| WapA |
| WapA |
| [ |
| SMU_63C |
| SMU_63C |
| [ |
1 CNS: coagulase negative staphylococci.
Figure 1Schematic representation of the genes involved in the formation of intrinsic amyloids, the drugs targeting such structures and their mechanism of action. (a) The formation of E. coli and S. Typhimurium curli amyloids is affected by several drugs, which act by different mechanisms: (i) stabilization of CsgA monomeric subunits; (ii) formation of amorphous or non-amyloidogenic aggregates; (iii) disaggregation of already-formed fibers; (iv) prevention of CsgB polymerization; (v) solubilization of CsgB; (vi) activation of the cell surface stress response, which reduces the expression of the curli regulator CsgD. (b) Pseudomonas Fap amyloids are inhibited by EGCG and PGG polyphenols, which lead FapC to off-pathway oligomers, remodeling fibers into amorphous aggregates and retaining quorum-sensing molecules.
Figure 2Schematic representation of the genes involved in the assembly of facultative amyloids, the drugs targeting such structures and their mechanism of action. (a) Drugs targeting S. aureus PSMs act by several mechanisms that involve the stabilization of PSM α-sheet structure and fiber disassembly. (b) B. subtilis TapA polymerization is inhibited by AA-861 and parthenolide. (c) The flavonoids quercetin, myricetin, and scutellarein inhibit polymerization of the Bap amyloid aggregates by stabilization of the Bap protein. (d) Polymerization of the amyloids S. mutants WapA and AgII/C123 is inhibited by AA-861, Tannic acid (TA), and EGCG and indirectly by the AFhPs and P1 peptides. SMU_63c amyloids are inhibited by EGCG.
Anti-biofilm agents targeting bacterial amyloids.
| Type | Amyloid Inhibitors | Anti-Biofilm Effect | Bacterial Amyloid Target | Eukaryotic Amyloid Target | Reference |
|---|---|---|---|---|---|
| Peptides | ANK6 | CsgA | Aβ | [ | |
| DB3DB3 | CsgA | Aβ | [ | ||
| AP90 |
| PSMα1 | ND | [ | |
| AFhPs |
| ND | ND | [ | |
| P1 |
| ND | ND | [ | |
| Proteins | TTR |
| CsgA | Aβ, HepF-N | [ |
|
| ND | ||||
| Antibodies | 3H3 | Curli | Aβ, TTR, Tau | [ | |
| Molecular tweezers | CLR01 |
| PSMα1 | Aβ, α-syn, Tau | [ |
| CLR05 |
| PSMα1 | Aβ, α-syn, Tau | [ | |
| Curlicides | FN075 |
| Curli | Aβ | [ |
| BibC6 |
| Curli | ND | [ | |
| VA028 |
| Curli | ND | [ | |
| Bioactive compounds | AA-861 |
| TasA | New1 | [ |
|
| P1 | [ | |||
| Parthenolide |
| TasA | New1 | [ | |
| Polyphenols | EGCG |
| CsgA | Aβ, α-syn, Tau | [ |
| FapC | [ | ||||
|
| P1 | [ | |||
|
| PSMα1PSMα4 | [ | |||
| PGG | FapC | Aβ | [ | ||
| Tannic acid |
| P1 | Prion PrP, Aβ | [ | |
| Luteolin |
| CsgA | Aβ, α-syn | [ | |
| Morin |
| CsgA | Aβ, α-syn | [ | |
| Myricetin |
| CsgA | Aβ, α-syn | [ | |
| Quercetin |
| CsgA | Aβ, α-syn | [ | |
| Phloretin |
| CsgA | Aβ, αSA53T | [ |
ND: non determined; Aβ: Amyloid β; α-syn: α-synuclein; αSA53T: mutant form of α-synuclein.